← GLP-1 receptor agonists × cardiovascular events

TrialDiabetes & vascular disease research2018

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.

Michael A Nauck et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT01179048. The trial’s primary report, PMID 27295427, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 864 people · 2018

Range includes no effect

No clear effect on cardiovascular events

Doesn’t vote: a later paper about the trial

−9%−34% to +26%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.91, 95% CI 0.66–1.26

One number in the abstract

the abstract, start to end

… placebo ( n = 85, 26.7%; hazard ratio: 0.91; 95% confidence interval: 0.66, …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.910.66–1.26
GLP-1 receptor agonistsCardiovascular events
1 / 3

12 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01179048phase 39,341 enrolled2010a later paper about it
Full record →Abstract, authors, funding and every citing paper · PMID 29947247